Orinko(SH:688219)2024-04-22 12:34Financial Performance - The company's operating revenue for Q1 2024 was CNY 1,275,320,470.70, representing a 14.22% increase compared to CNY 1,116,505,570.75 in the same period last year[5]. - Net profit attributable to shareholders for Q1 2024 was CNY 43,243,336.29, a significant increase of 143.13% from CNY 17,957,163.11 in the previous year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 32,962,867.24, up 117.24% from CNY 13,099,483.21 year-on-year[5]. - Basic earnings per share for Q1 2024 were CNY 0.10, reflecting a 150.00% increase from CNY 0.04 in the previous year[6]. - Net profit for Q1 2024 was CNY 46,379,979.27, compared to CNY 16,521,817.25 in Q1 2023, representing a significant increase of 180.5%[23]. - Earnings per share for Q1 2024 were CNY 0.10, up from CNY 0.04 in Q1 2023, indicating a 150% increase[24]. Cash Flow - The net cash flow from operating activities reached CNY 265,484,503.75, a remarkable increase of 605.10% compared to CNY 37,652,232.66 in the same period last year[6]. - Cash flow from operating activities in Q1 2024 was CNY 1,398,695,851.08, compared to CNY 1,130,437,104.07 in Q1 2023, marking a 23.7% increase[26]. - The net cash flow from operating activities for Q1 2024 was ¥265,484,503.75, a significant increase from ¥37,652,232.66 in Q1 2023, representing a growth of approximately 608%[27]. - The net cash flow from financing activities was -¥90,371,281.77, an improvement from -¥127,202,271.02 in Q1 2023, showing a reduction in cash outflow[28]. - The total cash outflow for financing activities was ¥266,461,661.05, down from ¥456,202,271.02 in Q1 2023, reflecting a decrease of approximately 41.6%[28]. Research and Development - Total R&D investment amounted to CNY 58,551,300.71, which is a 39.72% increase from CNY 41,905,139.34 in the same period last year[6]. - Research and development expenses for Q1 2024 totaled CNY 58,551,300.71, an increase from CNY 41,905,139.34 in Q1 2023, reflecting a 39.7% rise[22]. - R&D expenditure accounted for 4.59% of operating revenue, up 0.84 percentage points from 3.75% in the previous year[6]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 6,208,862,578.15, a decrease of 5.18% from CNY 6,547,935,190.42 at the end of the previous year[6]. - The company's current assets totaled RMB 3,750,797,905.93, down from RMB 4,164,857,502.60 in the previous period, indicating a decline of approximately 9.9%[19]. - The total liabilities decreased to RMB 3,750,797,905.93 from RMB 4,164,857,502.60, indicating a reduction of approximately 9.9%[19]. - The total liabilities as of Q1 2024 were CNY 4,254,342,841.05, down from CNY 4,636,782,715.69 in the previous year[21]. - The total equity attributable to shareholders increased to CNY 1,956,688,398.96 in Q1 2024 from CNY 1,916,457,779.57 in Q1 2023, a growth of 2.1%[21]. Shareholder Information - The company reported a total of 10,740,000 shares held in the repurchase special securities account, accounting for 2.34% of the total shares[13]. - The top ten shareholders did not report any related party relationships or concerted action agreements[13]. - The company has not disclosed any significant changes in the shareholding structure due to the transfer of shares among the top ten shareholders[16]. Inventory and Receivables - Accounts receivable decreased to RMB 1,524,927,935.61 from RMB 1,644,717,330.63, reflecting a decline of about 7.3%[18]. - Inventory levels decreased significantly from RMB 630,325,168.54 to RMB 505,355,414.39, representing a reduction of approximately 19.8%[19]. Other Income and Expenses - The company experienced a significant increase in other income, which rose to CNY 30,967,068.48 in Q1 2024 from CNY 3,191,708.85 in Q1 2023[23]. - Cash paid for employee compensation was ¥125,950,684.63, slightly up from ¥123,517,148.63 in Q1 2023, indicating a marginal increase[27].